Word: myeloma
(lookup in dictionary)
(lookup stats)
Dates: during 2000-2009
Sort By: most recent first
(reverse)
...Cambridge, Massachusetts, Millennium Pharmaceuticals is focusing on proteins called proteasomes, which evidently play a role in giving cancer cells unnaturally long lives. The company is in Phase II trials with LDP341, a proteasome-inhibiting substance that is showing promise against multiple myeloma and chronic lymphocytic leukemia. Phase I studies on the top five solid tumors (breast, pancreatic, prostate, lung and colon) are under way, and at this point the inhibitor seems to be working?at least in mice...
...years ago, Mohammad Omidian, 58, a general contractor from Orinda, Calif., had failed to respond to chemotherapy treatments for multiple myeloma that was eating away at his bones. He had shrunk 3 in. and was so weak, he says, "I could not sneeze without holding on to something." His doctors put him on Dendreon's experimental treatment Mylovenge, which required extracting dendritic cells from Omidian's blood, mixing them with molecules from myeloma cells and then returning them to the patient so they could deliver a swift kick to his immune system. Within two weeks, Omidian felt strong enough...
...dozen treatments aimed at halting that process, including some old-line drugs that have turned out to have antiangiogenic properties. Thalidomide, which caused devastating birth defects in some 12,000 children worldwide before it was withdrawn in the early 1960s, is finding a new lease on life against multiple myeloma and liver cancers. Pharmaceutical giant Bristol-Myers Squibb is testing an antiangiogenic drug that was initially developed to keep cancer from worming its way into surrounding tissue. It's also investigating whether low, steady doses of traditional chemotherapy may be able to beat back blood vessels, a treatment that would...
...years ago, Mohammad Omidian, 58, a general contractor from Orinda, Calif., had failed to respond to chemotherapy treatments for multiple myeloma that was eating away at his bones. He had shrunk 3 in. and was so weak, he says, "I could not sneeze without holding on to something." His doctors put him on Dendreon’s experimental treatment Mylovenge, which required extracting dendritic cells from Omidian’s blood, mixing them with molecules from myeloma cells, and then returning them to him so they could deliver a swift kick to his immune system. Within two weeks, Omidian felt strong enough...
...treatments aimed at halting that process, including some old-line drugs that have turned out to have anti-angiogenic properties. Thalidomide, which caused devastating birth defects in some 12,000 children worldwide before it was withdrawn in the early 1960s, is finding a new lease on life against multiple myeloma and liver cancers. Pharmaceutical giant Bristol-Myers Squibb is testing an antiangiogenic drug that was initially developed to keep cancer from worming its way into surrounding tissue. It’s also investigating whether low, steady doses of traditional chemotherapy may be able to beat back blood vessels, a treatment that...